Login
$VSTM
$7.73 +$0.03 (0.39%) After hours

$VSTM 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Regulation FD Disclosure

Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION NOVEMBER 2026

14 Oct 2026 8-K: Other Events

Introductory. Verastem, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 30,937,500 shares (the “Shares”) of its common stoc...

14 Oct 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +2 more

VS - 7375 : Potential Best - in - Class KRAS G12D (ON/OFF) Inhibitor R&D Update October 14, 2026

06 Aug 2026 8-K: Results of Operations and Financial Condition

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million

07 Aug 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

This Amendment No. 3 to Note Purchase Agreement (this “Amendment”), dated as of the date first set forth above, is entered into by and among Verastem, Inc., a Delaware corporation (“Issuer”), the Persons listed on the signature pages her...

23 Jun 2026 8-K: Regulation FD Disclosure; Other Events

VS - 7375 : Potential Best - in - Class KRAS G12D (ON/OFF) Inhibitor R&D Update Call June 23, 2026

17 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

26 May 2026 8-K: Submission of Matters to a Vote of Security Holders

The 2026 annual meeting of stockholders (the “Annual Meeting”) of Verastem, Inc. (the “Company”) was held in Needham, Massachusetts on May 21, 2026. At the Annual Meeting, the stockholders considered and acted upon the following proposals:

07 May 2026 8-K: Regulation FD Disclosure

Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A Y 2 0 2 6

04 Mar 2026 8-K: Regulation FD Disclosure

Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A R C H 2 0 2 6

04 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

08 Jan 2026 8-K: Regulation FD Disclosure

Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION JANUARY 2026

31 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

19 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

As we have discussed, your employment with Verastem, Inc. (the “Company”) will terminate, effective as of December 19, 2025 (the “Separation Date”). Please consider this letter as written notice under Paragraph 10 of your Employment Agre...

17 Nov 2025 8-K: Other Events

Introductory. Verastem, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 8,543,794 shares (the “Shares”) of its common stock...

04 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $11.2 million

23 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

20 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

08 Sep 2025 8-K: Regulation FD Disclosure

Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers Corporate Presentation | September 2025

13 Aug 2025 8-K: Regulation FD Disclosure; Other Events

GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support